Eli Lilly Secures Historic Oral GLP-1 Weight-Loss Pill Approval in China

RecentNews.uk

Eli Lilly has secured approval for the first oral GLP-1 weight-loss tablet in China.

The decision provides Eli Lilly with a key advantage over main competitor Novo Nordisk.

Oral formulations eliminate the need for injection pens and cold-chain refrigeration.

Tablet manufacturing could help ease global supply shortages that have impacted injectable drugs.

UK regulators will be closely monitoring international outcomes as oral GLP-1 applications progress.

Would you prefer a daily weight-loss pill over a weekly injection if offered by your doctor?

Tap below to vote and see what others think.